Brought to you by 
Pfizer licenses Phytopharm obesity candidate
29 Mar 2011
Executive Summary
Phytopharm PLC (public UK biotech developing drugs from plant sources) licensed Pfizer the exclusive worldwide right to develop and market P57, a preclinical appetite suppressant derived from an extract of an undisclosed South African plant.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer licenses Phytopharm obesity candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice